Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
XERIS PHARMACEUTICALS INC (XERS)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 | Jun-30-20 | Jun-05-20 | Mar-31-20 | Mar-05-20 |
| | 10-Q | 8-K | 10-K | 10-Q | 10-Q | 8-K | 10-Q | 8-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | 100.0% | |
| Cost of goods sold | 34.4% | 35.3% | 46.3% | 45.3% | 66.1% | | 57.9% | |
| Gross profit | 65.6% | 64.7% | 53.7% | 54.7% | 33.9% | | 42.1% | |
| Selling, general and administrative | 238.6% | 268.6% | | 518.5% | 1403.6% | | 2168.6% | |
| Research and development | 55.2% | 69.1% | 103.8% | 191.6% | 748.5% | | 1620.6% | |
| General and administrative | | | 89.3% | | | | | |
| EBITDA | -222.5% | -267.4% | -407.2% | -649.0% | -2102.2% | | -3725.1% | |
| Depreciation | 4.5% | | 7.3% | 9.5% | 25.5% | | 38.0% | |
| EBIT | -227.0% | -271.7% | -414.4% | -658.5% | -2127.7% | | -3763.1% | |
| Pre-tax income | -250.9% | -303.2% | -452.1% | -696.4% | -2241.8% | | -3892.0% | |
| Income taxes | 0.7% | 0.4% | 0.5% | 2.4% | 6.5% | | 13.8% | |
| Net income | -251.5% | -303.6% | -452.7% | -698.8% | -2248.3% | | -3905.8% | |
|